FDA Grants 19 First Generic Approvals in Q1 2026, Led by Complex Injectable and Inhalation Forms

Complex dosage form generics dominated FDA CDER's Q1 2026 first-approval roster, with injectable and inhalation products accounting for the majority of the 19 ANDAs cleared between January and March, a signal that manufacturers and contract development organizations are advancing capability in technically demanding manufacturing categories.

Three separate applicants, Hainan Poly Pharm., MSN Laboratories, and Micro Labs, received simultaneous first-generic approvals for Brivaracetam Injection on February 23, 2026, referencing UCB's Briviact. MSN Laboratories also secured approval for the oral solution form four days earlier. The parallel approvals reflect CDER's prioritization policy for first generics and indicate that multiple ANDA sponsors had cleared the sterility assurance, container-closure integrity, and process validation requirements for this pediatric-indicated injectable concurrently. For QA directors managing sterile fill-finish lines, the competitive compression here is notable: three market entrants on day one narrows the window for volume capture and raises the bar on launch readiness.

Mylan Pharmaceuticals secured the first generic for Aprepitant Injection (reference: Aponvie) on March 5, 2026, while Sagent Pharmaceuticals cleared Norepinephrine Bitartrate in 5% Dextrose Injection on March 26. Both are parenterals requiring validated aseptic processing under 21 CFR Part 211 and alignment with ICH Q10 pharmaceutical quality system expectations. Norepinephrine in a premixed dextrose vehicle adds formulation complexity, stability, pH control, and compatibility with primary packaging all represent documented ANDA review touchpoints.

Beyond injectables, Glenmark Specialty SA gained first-generic status for Fluticasone Propionate Aerosol (Flovent HFA) and Armstrong Pharmaceuticals for Ipratropium Bromide Aerosol (Atrovent HFA), both on or before March 3, 2026. Pressurized metered-dose inhalers carry device-drug combination considerations under 21 CFR Part 4 and require device constituent part documentation alongside the standard ANDA package, a manufacturing and regulatory burden that has historically limited the applicant pool.

Oral solid and tablet generics rounded out the quarter: Actavis Laboratories FL secured approval for Rifaximin Tablet (Xifaxan) on March 19; Teva Pharmaceuticals USA for Ferric Citrate Tablet (Auryxia) on March 11; Aurobindo Pharma for Citalopram Hydrobromide Capsule on March 13; and DifGen Pharmaceuticals for Mesalamine ER Capsule (Pentasa) on March 10. The extended-release mesalamine approval is relevant for manufacturers operating modified-release coating lines, where dissolution profile equivalence remains a common deficiency in Complete Response Letters.

The Q1 2026 cohort's concentration in sterile injectables and inhalation products tracks with CDER's stated priority review commitments for complex generics, and API suppliers serving these applicants should expect accelerated qualification timelines as launch preparation moves into commercial-scale process performance qualification.

Source: FDA CDER, First-Time Generic Drug Approvals 2026 via FDA.gov, May 22, 2026.